Tesamorelin in Minnesota: Egrifta Approval and Compounding Explained

HealthRX.com

Egrifta is the FDA-approved route, compounded is not

Print or save as PDF

See the public record for Tesamorelin

  • Approved products / Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial)
  • First approved / November 10, 2010, application BLA 022505
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy
  • Weight loss / Not indicated; the label describes a weight-neutral effect
  • How it works / GHRH analog; stimulates release of the body's own growth hormone
  • Compounded tesamorelin / Not FDA-approved; in no FDA compounding category
  • Sport / WADA prohibits it at all times (S2.2.4)

Is tesamorelin an approved drug in the United States?

Yes. Egrifta (tesamorelin acetate) was first approved on November 10, 2010, under application BLA 022505 [7]. The current products are Egrifta SV, a 2 mg vial, and Egrifta WR, an 11.6 mg vial, both once-daily subcutaneous injections with labels dated July 29, 2026 [1][2]. The doses differ — 1.4 mg (0.35 mL) for SV, 1.28 mg (0.16 mL) for WR — as do the diluents and storage, and the labels state the two are not substitutable [1][2].

What is it approved to treat?

One thing: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy [1][2]. The label says long-term cardiovascular safety has not been established, says to consider the risk and benefit of continuing in patients who have not had a reduction in visceral adipose tissue, and says the drug is not indicated for weight loss management because it has a weight-neutral effect [1]. In a 26-week trial of 412 HIV-infected adults with excess abdominal fat, visceral fat fell 15.2% on 2 mg daily versus a 5.0% rise on placebo [8].

Does the Egrifta approval cover compounded tesamorelin?

No. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [6]. Tesamorelin is not on FDA's page of bulk substances that may present significant safety risks when compounded, and it appears in no category of FDA's lists for state-licensed pharmacies and outsourcing facilities, so FDA has made no category-based statement about compounding it [3][4][5]. It is also not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 [9].

Questions worth asking

Choose the questions you want to keep

What does the Egrifta label flag?

Contraindications are disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [1][2]. The label reports that tesamorelin raises IGF-1 and says to monitor IGF-1 during treatment and consider discontinuation if levels stay elevated, for example above 3 SDS; among patients treated 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS [1]. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26, a hazard ratio of about 3.3 [1]. Injection site reactions occurred in 25% versus 14% over the first 26 weeks, and hypersensitivity reactions in 4%; the label says to advise patients to seek immediate medical attention and stop treatment if a hypersensitivity reaction is suspected [1].

Is tesamorelin prohibited in sport?

Yes. WADA's Prohibited List names tesamorelin in S2.2.4 among growth hormone releasing factors, prohibited at all times, in and out of competition, and it is on both the 2026 and 2027 Lists [10][11].

Is tesamorelin legal in Minnesota?
Egrifta SV and Egrifta WR are FDA-approved prescription products for HIV lipodystrophy, while compounded tesamorelin is not FDA-approved [1][2][6].
Is Egrifta a weight-loss drug?
No. The label says it is not indicated for weight loss management because it has a weight-neutral effect; its approved use is excess abdominal fat in HIV-infected adults with lipodystrophy [1][2].
Does Egrifta's approval cover compounded tesamorelin?
No. Compounded drugs are not FDA-approved, and Egrifta's approval does not make a compounded product FDA-approved [9][6].
Are Egrifta SV and Egrifta WR interchangeable?
No. Egrifta SV is dosed at 1.4 mg from a 2 mg vial and Egrifta WR at 1.28 mg from an 11.6 mg vial, with different diluents and storage, and the labels state they are not substitutable [1][2].
Show all 11 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  2. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  4. U.S. Food and Drug Administration.
  5. U.S. Food and Drug Administration.
  6. Official web page.
  7. Drugs@FDA: FDA-Approved Drugs.
  8. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
  9. Official web page.
  10. World Anti-Doping Agency.
  11. World Anti-Doping Agency.
Clinical research record review in a laboratory setting
Clinical research record review in a laboratory setting. Image: HealthRX.com clinical research illustration